Cargando…

Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols

PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cheng, Xu, Xiaochun, Folaron, Margaret, Gunn, Jason R., Hodge, Sassan, Chen, Eunice Y., Hoopes, P. Jack, Tichauer, Kenneth M., Samkoe, Kimberley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527767/
https://www.ncbi.nlm.nih.gov/pubmed/34651290
http://dx.doi.org/10.1007/s11307-021-01656-3
_version_ 1784801146005618688
author Wang, Cheng
Xu, Xiaochun
Folaron, Margaret
Gunn, Jason R.
Hodge, Sassan
Chen, Eunice Y.
Hoopes, P. Jack
Tichauer, Kenneth M.
Samkoe, Kimberley S.
author_facet Wang, Cheng
Xu, Xiaochun
Folaron, Margaret
Gunn, Jason R.
Hodge, Sassan
Chen, Eunice Y.
Hoopes, P. Jack
Tichauer, Kenneth M.
Samkoe, Kimberley S.
author_sort Wang, Cheng
collection PubMed
description PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targeted agents and the variance of fluorescence signal. Paired-agent imaging (PAI) employs co-administration of an untargeted imaging agent with a molecular targeted agent, providing a normalization factor to minimize nonspecific and varied signals. The resulting measured binding potential is quantitative and equivalent to in vivo immunohistochemistry of the target protein. This study demonstrates that PAI improves the accuracy of tumor-to-healthy tissue discrimination compared to single-agent imaging for in vivo FGS. PROCEDURES: PAI using a fluorescent anti-epidermal growth factor receptor (EGFR) affibody molecule (ABY-029, eIND 122,681) with untargeted IRDye 700DX carboxylate was compared to ABY-029 alone in an oral squamous cell carcinoma xenograft mouse model at 3 h after dye administration (n = 30). RESULTS: PAI significantly enhanced tumor discrimination, as compared to ABY-029 alone in low EGFR-expressing tumors and highly heterogeneous populations including multiple cell lines with varying expression (diagnostic accuracy: 0.908 vs. 0.854 and 0.908 vs. 0.822; and ROC curve AUC: 0.963 vs. 0.909 and 0.957 vs. 0.909, respectively) indicating a potential for universal FGS image thresholds to determine surgical margins. In addition, PAI achieved significantly higher diagnostic ability than ABY-029 alone 0.25–5-h post injection and exhibited a stronger correlation to EGFR expression heterogeneity. CONCLUSION: The quantitative receptor delineation of PAI promises to improve the surgical therapeutic index of cancer resection in a clinically relevant timeline. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01656-3.
format Online
Article
Text
id pubmed-9527767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95277672023-03-01 Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols Wang, Cheng Xu, Xiaochun Folaron, Margaret Gunn, Jason R. Hodge, Sassan Chen, Eunice Y. Hoopes, P. Jack Tichauer, Kenneth M. Samkoe, Kimberley S. Mol Imaging Biol Research Article PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targeted agents and the variance of fluorescence signal. Paired-agent imaging (PAI) employs co-administration of an untargeted imaging agent with a molecular targeted agent, providing a normalization factor to minimize nonspecific and varied signals. The resulting measured binding potential is quantitative and equivalent to in vivo immunohistochemistry of the target protein. This study demonstrates that PAI improves the accuracy of tumor-to-healthy tissue discrimination compared to single-agent imaging for in vivo FGS. PROCEDURES: PAI using a fluorescent anti-epidermal growth factor receptor (EGFR) affibody molecule (ABY-029, eIND 122,681) with untargeted IRDye 700DX carboxylate was compared to ABY-029 alone in an oral squamous cell carcinoma xenograft mouse model at 3 h after dye administration (n = 30). RESULTS: PAI significantly enhanced tumor discrimination, as compared to ABY-029 alone in low EGFR-expressing tumors and highly heterogeneous populations including multiple cell lines with varying expression (diagnostic accuracy: 0.908 vs. 0.854 and 0.908 vs. 0.822; and ROC curve AUC: 0.963 vs. 0.909 and 0.957 vs. 0.909, respectively) indicating a potential for universal FGS image thresholds to determine surgical margins. In addition, PAI achieved significantly higher diagnostic ability than ABY-029 alone 0.25–5-h post injection and exhibited a stronger correlation to EGFR expression heterogeneity. CONCLUSION: The quantitative receptor delineation of PAI promises to improve the surgical therapeutic index of cancer resection in a clinically relevant timeline. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01656-3. Springer International Publishing 2021-10-14 2023 /pmc/articles/PMC9527767/ /pubmed/34651290 http://dx.doi.org/10.1007/s11307-021-01656-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Wang, Cheng
Xu, Xiaochun
Folaron, Margaret
Gunn, Jason R.
Hodge, Sassan
Chen, Eunice Y.
Hoopes, P. Jack
Tichauer, Kenneth M.
Samkoe, Kimberley S.
Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title_full Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title_fullStr Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title_full_unstemmed Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title_short Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
title_sort improved discrimination of tumors with low and heterogeneous egfr expression in fluorescence-guided surgery through paired-agent protocols
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527767/
https://www.ncbi.nlm.nih.gov/pubmed/34651290
http://dx.doi.org/10.1007/s11307-021-01656-3
work_keys_str_mv AT wangcheng improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT xuxiaochun improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT folaronmargaret improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT gunnjasonr improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT hodgesassan improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT cheneunicey improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT hoopespjack improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT tichauerkennethm improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols
AT samkoekimberleys improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols